Valore202020212022202320242025TTMSpese di vendita, generali e amministrative1.08 B1.02 B1.1 B1.16 B1.01 B962.4 M962.4 MRicerca e sviluppo177.7 M122 M123.1 M122.5 M112.2 M95.4 M95.4 MReddito operativo115.4 M410.4 M78.9 M151.9 M112.9 M-1.12 B-1.12 BProventi non operativi, Totale-17.2 M-53.5 M-92.5 M10.4 M900 K-27.5 M-13.2 MOneri finanziari, al netto degli interessi capitalizzati-1.6 M-3 M02.9 M9.4 M9.5 M9.5 MProventi non operativi, esclusi gli oneri finanziari1.6 M-23.8 M-39.4 M-2.9 M-9.4 M-23.8 M-9.5 MEntrate/uscite straordinarie-17.2 M-26.7 M-53.1 M10.4 M900 K-13.2 M-13.2 MUtile al lordo delle imposte-296.7 M294 M-100.9 M-8.3 M-80.7 M-1.3 B-1.3 BQuota di utile———-1.9 M-1.5 M—-34.3 MImposte13.2 M389.6 M-8.2 M-3.9 M80 M104.4 M104.4 MInteressi di minoranza———————Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate-162.6 M-130.9 M-130.9 M-4.4 M-160.7 M-1.4 B-1.4 BAttività cessate—62 M-9.7 M-8.3 M-11.1 M-23.1 M-23.1 MUtile netto-162.6 M-68.9 M-140.6 M-12.7 M-171.8 M-1.43 B-1.43 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-162.6 M-68.9 M-140.6 M-12.7 M-171.8 M-1.43 B-1.43 BUtile base per azione (EPS base)-1.19-0.52-1.04-0.09-1.25-10.29-10.29Utile diluito per azione (EPS diluito)-1.19-0.52-1.04-0.09-1.25-10.29-10.29Numero medio di azioni ordinarie in circolazione136.1 M133.6 M134.5 M135.3 M137.4 M138.5 M552.9 MAzioni diluite in circolazione136.1 M133.6 M134.5 M135.3 M137.4 M138.5 M553.3 MEBITDA369 M597.6 M261.5 M337.6 M438.8 M-784.7 M-784.7 MEBIT-15.8 M285.4 M-77.1 M-21.9 M112.9 M-1.12 B-1.12 BCosto del fatturato3.25 B2.72 B3 B2.98 B2.83 B2.76 B2.76 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)384.8 M312.2 M338.6 M359.5 M325.9 M337.5 M337.5 M
Perrigo Company plc
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.